PI3K alpha (inhibitor)

Class

potent, selective, oral inhibitor of the class I PI3K alpha isoform (IC50 21 nmol/L), including PIK3CA mutants, with >100-fold selectivity over PI3Kβ/γ/δ and mTOR

Pathway

selective PI3Kα inhibition blocks PI3K/AKT/mTOR pathway signaling in PIK3CA-altered tumor cells, promoting apoptosis and growth inhibition while limiting the toxicity seen with pan-PI3K inhibitors

Phosphoinositide 3-kinase alpha (PI3Kα) is an enzyme that relays signals from cell-surface growth factor receptors to internal machinery controlling cell growth, survival, and metabolism. It is encoded in part by the gene PIK3CA, one of the most frequently mutated genes across solid tumors. Mutations in PIK3CA lock the enzyme into an active state, driving continuous signaling through the PI3K/AKT/mTOR pathway even without external growth signals, which supports uncontrolled tumor cell proliferation and resistance to cell death. Selectively inhibiting the alpha isoform, rather than blocking all PI3K family members or the downstream node mTOR, aims to interrupt this abnormal signaling in mutation-bearing tumor cells while sparing other isoforms (beta, gamma, delta) that serve largely separate physiological roles, such as platelet function and immune cell signaling. This isoform-selective approach is intended to reduce the broader toxicity historically associated with older, non-selective ('pan') PI3K inhibitors. The mechanism is relevant across cancers where PIK3CA mutations or pathway activation occur, including breast and gynecologic tumors, and reflects a broader strategy in oncology of matching a drug's target selectivity to a tumor's specific genetic driver.